Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04772456 · ClinicalTrials.gov registry record · Phase 1

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

A Phase 1 study of Glioma, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT04772456: Recruiting Phase 1 study of Glioma, sponsored by University of Maryland, Baltimore.

NCT04772456 is a Phase 1 study of Glioma that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 5 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04772456, a Phase 1 study of Glioma, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).

Primary Outcome

To study the accuracy of hyperpolarized metabolic MRI to diagnose Glioma Cancer. We will compare the prediction of cancer from the MRI scan compared to actual diagnosis of cancer by any subsequent workup or procedure the participant undergoes. Prediction of cancer from MRI scan will be performed by assigning a standardized score . Actual diagnosis of cancer will be based on tissue pathology.

Conditions Studied

Glioma

Interventions

  • DRUG Hyperpolarized 13C-Pyruvate

Study Locations (1)

Maryland

  • Rosy Njonkou Tchoquessi - Baltimore

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2020-08-11
Est. Completion 2027-12-31
Phase Phase 1
University of Maryland, Baltimore

560 total trials

What NCT04772456 shows while recruiting

NCT04772456 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C-Pyruvate is the first listed.

NCT04772456 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT04772456 about?

NCT04772456 is a clinical study titled "Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas". The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added...

What is the current status of trial NCT04772456?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-08-11. Estimated completion is 2027-12-31.

What conditions does trial NCT04772456 study?

This clinical trial studies the following conditions: Glioma.

What interventions are being tested in trial NCT04772456?

The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG).

Who is sponsoring clinical trial NCT04772456?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04772456 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04772456's enrollment target sits among peer trials

5 86th of 87 higher than 1 of 87 other Glioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04772456

Source: ClinicalTrials.gov NCT04772456, the US trial registry maintained by the National Library of Medicine. NCT04772456 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.